Mallika Singh is a seasoned professional in the biopharmaceutical industry with over 8 years of experience. She is pursuing a Doctor of Public Health (DrPH) degree at New York Medical College (NYMC). Mallika’s research focuses on identifying systemic barriers to diverse representation in clinical trials and aims to leverage her expertise and research to contribute to increasing health equity and diversity in clinical trials.Throughout her career, Mallika has held key roles in global biopharmaceutical companies such as Regeneron, Biogen, and Amgen, gaining experience in stem cell research, clinical operations, Pharmacovigilance (Drug Safety), and Pharmacokinetics and Drug Metabolism (PKDM).

Her leadership role at Regeneron, where she spearheaded the implementation of a safety system and ensured regulatory adherence, has been instrumental in driving operational excellence and enhancing patient safety across global clinical trials by automating the distribution of critical patient safety information. As a Senior Research Associate within the PKDM department at Amgen, her efforts were integral in measuring the half-life of the target protein KRAS, guiding dose projections, and advancing the development and approval of LUMAKRAS, a fast-tracked cancer therapy targeting non-small cell lung cancer (NSCLC). Mallika’s achievements include winning the prestigious CIRM Bridges to Stem Cell Research award, which enabled her to undertake a year-long funded project on Amyotrophic Lateral Sclerosis (ALS) using induced pluripotent stem cell-derived neural progenitors at The Regenerative Medicine Institute, Cedars-Sinai Hospital, Los Angeles, CA.

Mallika’s dedication to increasing diversity in clinical trials extends beyond her academic pursuits. She actively engages with advocacy groups, community organizations, and industry stakeholders to raise awareness about the importance of diverse representation in research studies. Through her research, advocacy, and leadership, she aspires to create a more inclusive and equitable healthcare system where all individuals have equal opportunities to participate in and benefit from clinical research.